Drugs Made In America Acquisition Corp. Ordinary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMAA research report →
About the company
Drugs Made In America Acquisition Corp. functions as a special purpose acquisition company, commonly known as a blank check company. Its core mission is to seek out and ultimately acquire one or more existing businesses or their assets.
- CEO
- Roger Bendelac
- IPO
- 2025
- Employees
- 2
- HQ
- Fort Lauderdale, FL, US
Price Chart
- Market Cap
- $359.09M
- P/E
- 52.05
- P/S
- 0.00
- P/B
- 1.04
- EV/EBITDA
- -136.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2.88%
- ROIC
- -1.09%
- Revenue
- $0 · 0.00%
- Net Income
- $5.94M · 1240317.75%
- EPS
- $0.19 · 439.29%
- Op Income
- $-2,816,013
- FCF YoY
- -182675.25%
- 52W High
- $10.65
- 52W Low
- $10.17
- 50D MA
- $10.60
- 200D MA
- $10.44
- Beta
- 0.00
- Avg Volume
- 114.75K
Get TickerSpark's AI analysis on DMAA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 25 | Drugs Made In America Acquisition LLC | buy | 30,000 |
| Feb 18, 25 | Drugs Made In America Acquisition LLC | buy | 30,000 |
| Feb 18, 25 | Stockwell Lynn | buy | 30,000 |
| Feb 18, 25 | Stockwell Lynn | buy | 30,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | buy | 400,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | other | 400,000 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | sell | 5,698,363 |
| Jan 29, 25 | Drugs Made In America Acquisition LLC | buy | 400,000 |
| Jan 29, 25 | Stockwell Lynn | other | 400,000 |
| Jan 29, 25 | Stockwell Lynn | sell | 5,698,363 |
Our DMAA coverage
Recent articles, reports, and earnings notes.
No research on DMAA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DMAA report →Similar companies
Peers in the same neighborhood.